NCT07720466Not yet recruiting
Salivary Function and Dental Changes During GLP-1 Therapy
Prospective Evaluation of Salivary Calcium Levels, Salivary Function, and Dental Hard Tissue Changes in Patients Receiving GLP-1 Receptor Agonist Therapy
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
People who use glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, may experience changes in their oral health. Some people report dry mouth, changes in saliva, and increased wear of their teeth after starting these medicines. However, little is known about whether these medicines affect saliva and dental hard tissues. The purpose of this study is to evaluate changes in salivary calcium levels, salivary function, and dental hard tissues in adults who begin treatment with semaglutide or tirzepatide for obesity. Approximately 40 participants will be enrolled before starting GLP-1 receptor agonist therapy. Oral examinations, standardized intraoral photographs, saliva samples, and body weight measurements will be obtained before treatment and again after three months. Saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate. Dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index. The findings from this study may improve understanding of the effects of GLP-1 receptor agonists on oral health and help healthcare professionals identify and prevent possible dental complications during treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 14 Jul 2026
- Start date
- 17 Aug 2026
- Primary completion date
- 21 Oct 2026
- Lead sponsor
- Bilecik Seyh Edebali Universitesi
- Diseases
- Obesity
- NCT number
- NCT07720466
What you commit to
- Study type: Observational
- Planned participants: 40
- From 17 Aug 2026 to the primary completion date, 21 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous use of any GLP-1 receptor agonist.
- Use of medications known to markedly affect salivary secretion.
Other illness
- History of head and neck radiotherapy.
- Sjögren syndrome or other systemic diseases affecting salivary gland function.
- Chronic kidney disease.
- History of eating disorders associated with recurrent self-induced vomiting (e.g., bulimia nervosa).
- Medical conditions causing persistent vomiting or severe gastroesophageal disease unrelated to GLP-1 therapy.
Other
- Pregnancy or breastfeeding.
- Active orthodontic treatment.
- Severe dental erosion requiring restorative treatment at baseline.
- Edentulism or the absence of anterior teeth required for dental hard tissue assessment.
- Inability or unwillingness to comply with the study protocol or attend the 3-month follow-up visit.
Who the study is looking for
- Adults aged 18 years or older.
- Body mass index (BMI) ≥27 kg/m².
- Clinical decision by an endocrinologist to initiate semaglutide or tirzepatide therapy for obesity management.
- No previous treatment with GLP-1 receptor agonists.
- Willingness to participate and ability to provide written informed consent.
- Willingness to attend both the baseline and 3-month follow-up visits.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Periodontology, Bilecik Seyh Edebali University Faculty of Dentistry Coordinator of this site? Confirm its status | Bilecik | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.